Posted by Michael Wonder on 24 Oct 2023
Milestone Pharmaceuticals announces submission of new drug application to the US FDA for etripamil
24 October 2023 - Comprehensive data package includes positive results from pivotal Phase 3 RAPID trial which company believes demonstrates new calcium channel blocker, etripamil, is twice as effective and three times as fast as a placebo in restoring normal heart rhythm for patients suffering from paroxysmal supraventricular tachycardia.
Milestone Pharmaceuticals today announced the submission of a new drug application to the US FDA for etripamil for the treatment of paroxysmal supraventricular tachycardia.
